This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, C. H.
Right arrow Articles by Greenberg, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, C. H.
Right arrow Articles by Greenberg, M. L.

 Previous Article  |  Next Article 

J. Virol., 06 1995, 3771-3777, Vol 69, No. 6
Copyright © 1995, American Society for Microbiology

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion

CH Chen, TJ Matthews, CB McDanal, DP Bolognesi and ML Greenberg
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

We have previously reported that synthetic peptides representing the leucine zipper domain (DP107) and a second putative helical domain (DP178) of human immunodeficiency virus type 1 (HIV-1) gp41 exhibit potent anti-HIV activity. In this study we have used soluble recombinant forms of gp41 to provide evidence that the DP178 peptide and the DP178 region of gp41 associate with a distal site on the gp41 transmembrane protein whose interactive structure is influenced by the leucine zipper (DP107) motif. We also observed that a single coiled- coil-disrupting mutation in the leucine zipper domain transformed the recombinant gp41 protein from an inactive to an active inhibitor of HIV- 1 fusion and infectivity, which may be related to that finding. We speculate that this transformation results from liberation of the potent DP178-related sequence from a molecular clasp with a leucine zipper, DP107, determinant. The results are discussed in the context of two distinct conformations for the gp41 molecule and possible involvement of these two domains in structural transitions associated with HIV-1-mediated fusion. The results are also interpreted to suggest that the anti-HIV activity of the various gp41 derivatives (peptides and recombinant proteins) may be due to their ability to form complexes with viral gp41 and interfere with its fusogenic processes.


This article has been cited by other articles:

  • Ray, N., Blackburn, L. A., Doms, R. W. (2009). HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide. J. Virol. 83: 2989-2995 [Abstract] [Full Text]  
  • Chien, M.-P., Jiang, S., Chang, D.-K. (2008). The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. FASEB J. 22: 1179-1192 [Abstract] [Full Text]  
  • Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., Doms, R. W. (2007). Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. J. Virol. 81: 3240-3250 [Abstract] [Full Text]  
  • Xie, H., Belogortseva, N. I., Wu, J., Lai, W.-H., Chen, C.-h. (2006). Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Binding Domain of Porphyromonas gingivalis Gingipain.. Antimicrob. Agents Chemother. 50: 3070-3074 [Abstract] [Full Text]  
  • Labrosse, B., Morand-Joubert, L., Goubard, A., Rochas, S., Labernardiere, J.-L., Pacanowski, J., Meynard, J.-L., Hance, A. J., Clavel, F., Mammano, F. (2006). Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.. J. Virol. 80: 8807-8819 [Abstract] [Full Text]  
  • Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., Greenberg, M. L. (2005). Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro. J. Virol. 79: 12447-12454 [Abstract] [Full Text]  
  • Kinomoto, M., Yokoyama, M., Sato, H., Kojima, A., Kurata, T., Ikuta, K., Sata, T., Tokunaga, K. (2005). Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor. J. Virol. 79: 5996-6004 [Abstract] [Full Text]  
  • Reeves, J. D., Lee, F.-H., Miamidian, J. L., Jabara, C. B., Juntilla, M. M., Doms, R. W. (2005). Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization. J. Virol. 79: 4991-4999 [Abstract] [Full Text]  
  • Xu, L., Pozniak, A., Wildfire, A., Stanfield-Oakley, S. A., Mosier, S. M., Ratcliffe, D., Workman, J., Joall, A., Myers, R., Smit, E., Cane, P. A., Greenberg, M. L., Pillay, D. (2005). Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41. Antimicrob. Agents Chemother. 49: 1113-1119 [Abstract] [Full Text]  
  • Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., Debnath, A. K. (2004). N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion. Antimicrob. Agents Chemother. 48: 4349-4359 [Abstract] [Full Text]  
  • Greenberg, M. L., Cammack, N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54: 333-340 [Abstract] [Full Text]  
  • Reeves, J. D., Miamidian, J. L., Biscone, M. J., Lee, F.-H., Ahmad, N., Pierson, T. C., Doms, R. W. (2004). Impact of Mutations in the Coreceptor Binding Site on Human Immunodeficiency Virus Type 1 Fusion, Infection, and Entry Inhibitor Sensitivity. J. Virol. 78: 5476-5485 [Abstract] [Full Text]  
  • Shnaper, S., Sackett, K., Gallo, S. A., Blumenthal, R., Shai, Y. (2004). The C- and the N-terminal Regions of Glycoprotein 41 Ectodomain Fuse Membranes Enriched and Not Enriched with Cholesterol, Respectively. J. Biol. Chem. 279: 18526-18534 [Abstract] [Full Text]  
  • Moore, J. P., Doms, R. W. (2003). The entry of entry inhibitors: A fusion of science and medicine. Proc. Natl. Acad. Sci. USA 100: 10598-10602 [Abstract] [Full Text]  
  • Bosch, B. J., van der Zee, R., de Haan, C. A. M., Rottier, P. J. M. (2003). The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. J. Virol. 77: 8801-8811 [Abstract] [Full Text]  
  • Kilby, J. M., Eron, J. J. (2003). Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. NEJM 348: 2228-2238 [Full Text]  
  • Trivedi, V. D., Cheng, S.-F., Wu, C.-W., Karthikeyan, R., Chen, C.-J., Chang, D.-K. (2003). The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng Des Sel 16: 311-317 [Abstract] [Full Text]  
  • Giannecchini, S., Di Fenza, A., D'Ursi, A. M., Matteucci, D., Rovero, P., Bendinelli, M. (2003). Antiviral Activity and Conformational Features of an Octapeptide Derived from the Membrane-Proximal Ectodomain of the Feline Immunodeficiency Virus Transmembrane Glycoprotein. J. Virol. 77: 3724-3733 [Abstract] [Full Text]  
  • Markosyan, R. M., Cohen, F. S., Melikyan, G. B. (2003). HIV-1 Envelope Proteins Complete Their Folding into Six-helix Bundles Immediately after Fusion Pore Formation. Mol. Biol. Cell 14: 926-938 [Abstract] [Full Text]  
  • Ma, J., Kennedy-Stoskopf, S., Jaynes, J. M., Thurmond, L. M., Tompkins, W. A. (2002). Inhibitory Activity of Synthetic Peptide Antibiotics on Feline Immunodeficiency Virus Infectivity In Vitro. J. Virol. 76: 9952-9961 [Abstract] [Full Text]  
  • Follis, K. E., Larson, S. J., Lu, M., Nunberg, J. H. (2002). Genetic Evidence that Interhelical Packing Interactions in the gp41 Core Are Critical for Transition of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein to the Fusion-Active State. J. Virol. 76: 7356-7362 [Abstract] [Full Text]  
  • Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., Kappes, J. C. (2002). Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. Antimicrob. Agents Chemother. 46: 1896-1905 [Abstract] [Full Text]  
  • Liu, J., Wang, S., Hoxie, J. A., LaBranche, C. C., Lu, M. (2002). Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex. J. Biol. Chem. 277: 12891-12900 [Abstract] [Full Text]  
  • Zhu, C.-B., Zhu, L., Holz-Smith, S., Matthews, T. J., Chen, C. H. (2001). The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. Proc. Natl. Acad. Sci. USA 10.1073/pnas.261359098v1 [Abstract] [Full Text]  
  • Lu, M., Stoller, M. O., Wang, S., Liu, J., Fagan, M. B., Nunberg, J. H. (2001). Structural and Functional Analysis of Interhelical Interactions in the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein by Alanine-Scanning Mutagenesis. J. Virol. 75: 11146-11156 [Abstract] [Full Text]  
  • Eckert, D. M., Kim, P. S. (2001). Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. USA 98: 11187-11192 [Abstract] [Full Text]  
  • Chen, C.-H., Jin, L., Zhu, C., Holz-Smith, S., Matthews, T. J. (2001). Induction and Characterization of Neutralizing Antibodies against a Human Immunodeficiency Virus Type 1 Primary Isolate. J. Virol. 75: 6700-6704 [Abstract] [Full Text]  
  • Holz-Smith, S. L., Sun, I-C., Jin, L., Matthews, T. J., Lee, K.-H., Chen, C. H. (2001). Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564. Antimicrob. Agents Chemother. 45: 60-66 [Abstract] [Full Text]  
  • Melikyan, G. B., Markosyan, R. M., Hemmati, H., Delmedico, M. K., Lambert, D. M., Cohen, F. S. (2000). Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion. JCB 151: 413-424 [Abstract] [Full Text]  
  • Shen, W., Li, B., Wetzel, M. A., Rogers, T. J., Henderson, E. E., Su, S. B., Gong, W., Le, Y., Sargeant, R., Dimitrov, D. S., Oppenheim, J. J., Wang, J. M. (2000). Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. Blood 96: 2887-2894 [Abstract] [Full Text]  
  • Yang, X., Florin, L., Farzan, M., Kolchinsky, P., Kwong, P. D., Sodroski, J., Wyatt, R. (2000). Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution. J. Virol. 74: 4746-4754 [Abstract] [Full Text]  
  • Kingsley, D. H., Behbahani, A., Rashtian, A., Blissard, G. W., Zimmerberg, J. (1999). A Discrete Stage of Baculovirus GP64-mediated Membrane Fusion. Mol. Biol. Cell 10: 4191-4200 [Abstract] [Full Text]  
  • Ji, H., Shu, W., Burling, F. T., Jiang, S., Lu, M. (1999). Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion. J. Virol. 73: 8578-8586 [Abstract] [Full Text]  
  • Park, E. J., Quinnan, G. V. Jr. (1999). Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains. J. Virol. 73: 5707-5713 [Abstract] [Full Text]  
  • Su, S. B., Gong, W.-h., Gao, J.-L., Shen, W.-P., Grimm, M. C., Deng, X., Murphy, P. M., Oppenheim, J. J., Wang, J. M. (1999). T20/DP178, an Ectodomain Peptide of Human Immunodeficiency Virus Type 1 gp41, Is an Activator of Human Phagocyte N-Formyl Peptide Receptor. Blood 93: 3885-3892 [Abstract] [Full Text]  
  • Su, S. B., Gao, J.-l., Gong, W.-h., Dunlop, N. M., Murphy, P. M., Oppenheim, J. J., Wang, J. M. (1999). T21/DP107, A Synthetic Leucine Zipper-Like Domain of the HIV-1 Envelope gp41, Attracts and Activates Human Phagocytes by Using G-Protein-Coupled Formyl Peptide Receptors. J. Immunol. 162: 5924-5930 [Abstract] [Full Text]  
  • Esser, M. T., Mori, T., Mondor, I., Sattentau, Q. J., Dey, B., Berger, E. A., Boyd, M. R., Lifson, J. D. (1999). Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120. J. Virol. 73: 4360-4371 [Abstract] [Full Text]  
  • Lu, M., Ji, H., Shen, S. (1999). Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus Type 1 gp41: Implications for Viral Membrane Fusion. J. Virol. 73: 4433-4438 [Abstract] [Full Text]  
  • Chan, D. C., Chutkowski, C. T., Kim, P. S. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 95: 15613-15617 [Abstract] [Full Text]  
  • Jiang, S., Lin, K., Lu, M. (1998). A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein. J. Virol. 72: 10213-10217 [Abstract] [Full Text]  
  • Park, E. J., Vujcic, L. K., Anand, R., Theodore, T. S., Quinnan, G. V. Jr. (1998). Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes. J. Virol. 72: 7099-7107 [Abstract] [Full Text]  
  • Zhao, Y., Zhu, L., Benedict, C. A., Chen, D., Anderson, W. F., Cannon, P. M. (1998). Functional Domains in the Retroviral Transmembrane Protein. J. Virol. 72: 5392-5398 [Abstract] [Full Text]  
  • Wyatt, R., Sodroski, J. (1998). The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens. Science 280: 1884-1888 [Abstract] [Full Text]  
  • Rizzuto, C. D., Wyatt, R., Hernández-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., Sodroski, J. (1998). A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding. Science 280: 1949-1953 [Abstract] [Full Text]  
  • Chen, S. S.-L., Lee, S.-F., Hao, H.-J., Chuang, C.-K. (1998). Mutations in the Leucine Zipper-Like Heptad Repeat Sequence of Human Immunodeficiency Virus Type 1 gp41 Dominantly Interfere with Wild-Type Virus Infectivity. J. Virol. 72: 4765-4774 [Abstract] [Full Text]  
  • Rimsky, L. T., Shugars, D. C., Matthews, T. J. (1998). Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides. J. Virol. 72: 986-993 [Abstract] [Full Text]  
  • Munoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., Blumenthal, R. (1998). Dilation of the Human Immunodeficiency Virus-1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41. JCB 140: 315-323 [Abstract] [Full Text]  
  • Hesselgesser, J., Liang, M., Hoxie, J., Greenberg, M., Brass, L. F., Orsini, M. J., Taub, D., Horuk, R. (1998). Identification and Characterization of the CXCR4 Chemokine Receptor in Human T Cell Lines: Ligand Binding, Biological Activity, and HIV-1 Infectivity. J. Immunol. 160: 877-883 [Abstract] [Full Text]  
  • Carr, C. M., Chaudhry, C., Kim, P. S. (1997). Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl. Acad. Sci. USA 94: 14306-14313 [Abstract] [Full Text]  
  • Tan, K., Liu, J.-h., Wang, J.-h., Shen, S., Lu, M. (1997). Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94: 12303-12308 [Abstract] [Full Text]  
  • Lacey, S. F., McDanal, C. B., Horuk, R., Greenberg, M. L. (1997). The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1. Proc. Natl. Acad. Sci. USA 94: 9842-9847 [Abstract] [Full Text]  
  • Weissenhorn, W., Calder, L. J., Dessen, A., Laue, T., Skehel, J. J., Wiley, D. C. (1997). Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. Proc. Natl. Acad. Sci. USA 94: 6065-6069 [Abstract] [Full Text]  
  • Kliger, Y., Gallo, S. A., Peisajovich, S. G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., Shai, Y. (2001). Mode of Action of an Antiviral Peptide from HIV-1. INHIBITION AT A POST-LIPID MIXING STAGE. J. Biol. Chem. 276: 1391-1397 [Abstract] [Full Text]  
  • Dimitrov, A. S., Xiao, X., Dimitrov, D. S., Blumenthal, R. (2001). Early Intermediates in HIV-1 Envelope Glycoprotein-mediated Fusion Triggered by CD4 and Co-receptor Complexes. J. Biol. Chem. 276: 30335-30341 [Abstract] [Full Text]  
  • Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., Greenlee, W. J., Tagat, J. R., McCombie, S., Cox, K., Fawzi, A. B., Chou, C.-C., Pugliese-Sivo, C., Davies, L., Moreno, M. E., Ho, D. D., Trkola, A., Stoddart, C. A., Moore, J. P., Reyes, G. R., Baroudy, B. M. (2001). SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98: 12718-12723 [Abstract] [Full Text]  
  • Zhu, C.-B., Zhu, L., Holz-Smith, S., Matthews, T. J., Chen, C. H. (2001). The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. Proc. Natl. Acad. Sci. USA 98: 15227-15232 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»